Bioidentical Hormone Replacement Therapy (BHRT) Imbalances can disrupt ovulation, menstrual cycles, and overall reproductive health
If no validated condition is available, temporary storage of unopened lyophilized material at approximately 20C in a tightly sealed, dry, light-protected container may be used as a conservative laboratory holding condition, but it must not be presented as a validated shelf-life claim
By adding cagrilintide's amylin pathway, CagriSema achieves approximately 20% weight loss, closing the gap with tirzepatide
However: Longer-term safety data (5+ years) is still being collected Individual risk factors vary significantly Regular medical monitoring essential for ongoing safety assessment Some individuals develop side effects requiring discontinuation Long-term cardiovascular benefits observed in some trials (SELECT trial with semaglutide) Healthcare providers should regularly reassess whether continued treatment remains appropriate for individual circumstances based on ongoing benefits, risks, and patient preferences